Month: May 2022

Lassila & Tikanoja plcStock exchange release12 May 2022 at 6.00 pm NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE OFFERING OF THE NOTES OR THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Lassila & Tikanoja plc issues EUR 75 million sustainability-linked notes due 2028 Lassila & Tikanoja plc (the “Company”) issues senior unsecured sustainability-linked notes in the amount of EUR 75 million (the “New Notes”). The New Notes will mature on 19 May 2028, bear a fixed annual interest at the rate of 3.375 per cent and have an issue price of 99.882 per cent. “Lassila & Tikanoja is proud to be among...

Quadient (Euronext Paris: QDT) will release its first-quarter 2022 sales on Tuesday, 7th June 2022 after the close of trading on the Euronext Paris stock exchange. Geoffrey Godet, Chief Executive Officer, and Laurent Du Passage, Chief Financial Officer, will host a live webcast and conference call to discuss the Group’s performance at 6:00pm CET (5:00pm BST) on the same day. The presentation will be conducted in English and will be followed by a Q&A session. Tuesday, 7th June 2022 6:00pm (CET), 5:00pm (BST) CONFERENCE CALL Please connect 10 minutes before the start of the live event by using the following dial-in numbers:France: +33 (0) 1 70 37 71 66 United States: +1 212 999 6659 United Kingdom (Standard International Access): +44 (0) 33 0551 0200 Password: QUADIENTWEBCAST The live webcast and the presentation slides will be...

Companion diagnostics (CDx) are developed in parallel to the drug using the drug-diagnostic co-development model LONDON, May 12, 2022 (GLOBE NEWSWIRE) — Oncology remains the largest segment for FDA-defined marketed drugs with CDx. The FDA has cleared or approved more than 40 CDx in the field of oncology. It is expected that oncology will likely remain the therapeutic area at the forefront of CDx in the future. Although precision medicine encompasses many areas, oncology is the area that is expected to exhibit high growth. The Companion Diagnostics Thematic Research Report offered by GlobalData Plc looks at the CDx medical devices market and some of the oncology biomarkers, indications, and diagnostic technologies being utilized. The market for biomarker testing continues to increase due to increases in disease, awareness, improved...

Canada’s affluent segment (covering HNWs and mass affluents) has experienced steady growth in recent years LONDON, May 12, 2022 (GLOBE NEWSWIRE) — In 2019, Canada’s ultra-wealthy population observed an increase in their share of wealth on account of high-performing equity and property markets. Between 2015 and 2019, growth was particularly pronounced in higher wealth bands. However, the pandemic brought the rapid HNW growth to an end. Canadian stock markets were characterized by heightened fluctuations because of falling consumer confidence in the country’s economic performance amid state-induced social distancing restrictions. This resulted in the investor population turning to safe-haven investments to limit their risk exposure. The Canada Wealth Management Market Research Report offered by GlobalData Plc focuses on the HNW segment....

BETHESDA, Md., May 12, 2022 (GLOBE NEWSWIRE) — Liquidity Services, (Nasdaq:LQDT), a leading global commerce company powering the circular economy, today announced Bill Angrick, Co-Founder, Chairman, and CEO, and Jorge Celaya, Executive Vice President and Chief Financial Officer, will participate in the upcoming Barrington Research Spring Investment Conference on May 19, 2022. The virtual conference will feature meetings with senior management from approximately 40 publicly-traded companies operating in the broadly-defined Business Services, Industrial, Broadcasting, and financial service sectors. Mr. Angrick and Mr. Celaya will conduct individual meetings with investors to discuss how Liquidity Services provides pioneering e-commerce marketplace solutions that continue to power the circular economy and build a better future for...

The global Augmented Reality (AR) market size was worth $7 billion in 2020 LONDON, May 12, 2022 (GLOBE NEWSWIRE) — The AR market is expected to grow at a CAGR of more than 35% during the forecast period. Augmented reality is a technology that allows the user to see the real world overlaid with digital data. AR technology may replace the smartphone as the primary connected device users carry around. Moreover, it will be a critical component of the metaverse – the next mega-theme that Big Tech has in its sights. COVID-19 has also fueled enterprise adoption of AR across sectors such as healthcare, law enforcement, and manufacturing, mainly for remote collaboration. The Augmented Reality Thematic Research Report offered by GlobalData Plc provides an overview of the global augmented reality market and identifies the key trends impacting...

Advertising technology (adtech) is a blanket term covering all software and services used to deliver and target digital advertisements LONDON, May 12, 2022 (GLOBE NEWSWIRE) — The internet advertising market size was valued at $438 billion in 2021 and will grow at a CAGR of more than 9% during 2021-2030.  The Advertising Tech Thematic Research Report offered by GlobalData Plc provides key trends impacting the growth of the theme over the next 12 to 24 months split into three categories: technology trends, macroeconomic trends, and regulatory trends, and comprehensive industry analysis, including forecasts for the global internet advertising market to 2030. The report gives details of M&A deals driven by the adtech theme, and a timeline highlighting milestones in the development of adtech. It also provides a detailed value chain...

Accepted abstracts include an oral presentation highlighting quality of life improvements with EMPAVELI® (pegcetacoplan)WALTHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that seven abstracts will be presented at the hybrid European Hematology Association (EHA) Congress to be held June 9-12 in Vienna, Austria. Data to be presented reinforce the robust efficacy and safety profile of EMPAVELI® (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). “Our presence at EHA this year continues to underscore the potential of EMPAVELI to become the new standard of care for all adults living with PNH,” said Federico Grossi, M.D., Ph.D., chief medical officer of Apellis. Oral Presentation:Effect...